Free Trial

Illumina (ILMN) Stock Forecast & Price Target

Illumina logo
$197.74 -9.27 (-4.48%)
As of 03:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Illumina - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
3
Hold
6
Buy
10

Based on 19 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Hold." Out of the 19 analysts, 3 have given a sell rating, 6 have given a hold rating, and 10 have given a buy rating for ILMN.

Consensus Price Target

$244.24
23.51% Upside
According to the 19 analysts' twelve-month price targets for Illumina, the average price target is $244.24. The highest price target for ILMN is $310.00, while the lowest price target for ILMN is $137.00. The average price target represents a forecasted upside of 23.51% from the current price of $197.75.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ILMN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Illumina and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ILMN Analyst Ratings Over Time

TypeCurrent Forecast
11/16/25 to 11/16/26
1 Month Ago
10/17/25 to 10/17/26
3 Months Ago
8/18/25 to 8/18/26
1 Year Ago
11/16/24 to 11/16/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
5 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
9 Hold rating(s)
Sell
3 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$244.24$225.94$188.40$115.00
Forecasted Upside23.51% Upside-13.94% Downside0.06% Upside-4.70% Downside
Consensus RatingHoldHoldHoldHold

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Illumina Stock vs. The Competition

TypeIlluminaHealthcare CompaniesBroader Market
Consensus Rating Score
2.37
2.32
2.52
Consensus RatingHoldHoldModerate Buy
Predicted Upside21.90% Upside116.80% Upside15.45% Upside
News Sentiment Rating
Positive News

See Recent ILMN News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
11/2/2026
Weiss Ratings logo
Weiss Ratings
2 of 5 stars
 UpgradeHold (C) ➝ Buy (B-)
11/2/2026
Citigroup Inc. logo
Citigroup
4 of 5 stars
Joanne Wuensch
Joanne Wuensch
3 of 5 stars
Boost TargetSell$113.00 ➝ $210.00-8.11%
10/30/2026
Evercore Inc logo
Evercore
3 of 5 stars
 Reiterated RatingUnderperform
10/30/2026Lower TargetOverweight$320.00 ➝ $300.00+27.12%
10/23/2026 DowngradeOverweight ➝ Equal Weight$275.00+2.02%
10/19/2026Boost TargetHold$205.00 ➝ $300.00+14.27%
10/13/2026Boost TargetHold$210.00 ➝ $270.00+0.35%
10/7/2026Boost TargetUnderweight$160.00 ➝ $200.00-26.88%
10/5/2026Boost TargetOutperform$230.00 ➝ $310.00+12.36%
10/1/2026Boost TargetBuy$226.00 ➝ $305.00+12.33%
9/29/2026Boost TargetOutperform$220.00 ➝ $300.00+11.63%
9/28/2026Boost TargetOverweight$225.00 ➝ $305.00+12.96%
9/9/2026UpgradeNeutral ➝ Buy$135.00 ➝ $260.00+23.19%
9/3/2026Boost TargetBuy$180.00 ➝ $235.00+9.48%
9/1/2026 DowngradeStrong-Buy ➝ Hold
8/5/2026 DowngradeHold
7/31/2026Reiterated RatingMarket Perform$215.00+4.83%
7/31/2026Boost TargetBuy$155.00 ➝ $225.00+13.72%
5/14/2026 UpgradeNeutral ➝ Outperform$155.00+6.90%
2/6/2026Set Target$137.00+13.26%
8/4/2025Boost TargetEqual Weight$100.00 ➝ $105.00+8.45%
7/11/2025DowngradeSector Outperform ➝ Sector Perform$125.00+24.94%
2/28/2025DowngradeStrong-Buy ➝ Hold$100.00+18.76%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 03:57 PM ET.


Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, November 12, 2026. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

Illumina
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Illumina, Inc.:

  • Illumina, Inc. recently reported third-quarter 2026 earnings that significantly exceeded market expectations, delivering $1.62 in earnings per share compared to the consensus estimate of $1.36, which demonstrates strong operational execution and profitability with a net margin of 19.72%.
  • The company has shown consistent revenue growth, with third-quarter 2026 revenue reaching $1.17 billion, a 4.2% increase year-over-year, and has raised its full-year 2026 revenue guidance to between $4.64 billion and $4.66 billion, indicating sustained demand for its sequencing technologies.
  • Illumina, Inc. is expanding its clinical oncology applications by introducing an ultrasensitive duplex sequencing workflow for molecular residual disease research, which enhances its ability to detect circulating tumor DNA and positions the company favorably in the growing precision medicine market.
  • Wall Street analysts have recently revised their outlooks upward, with TD Cowen raising its price target to $270.00 and Stifel Nicolaus increasing its target to $225.00, reflecting a consensus price target of $238.53 that suggests potential upside from the current trading levels.
  • The stock is currently trading at $209.55, which is below its 52-week high of $309.35, offering a potential entry point for investors who believe in the long-term growth of genomic sequencing and the company's strong return on equity of 28.38%.

Illumina
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Illumina, Inc. for these reasons:

  • Director Keith Meister has engaged in significant insider selling, disposing of over 300,000 shares in early November 2026 alone, which may signal a lack of confidence in the stock's near-term performance or a desire to reduce personal exposure to the company.
  • The stock has experienced a recent decline, trading down $3.38 to $209.55 on November 12, 2026, and has fallen below its 50-day moving average of $249.39, indicating short-term bearish momentum and potential technical weakness.
  • Illumina, Inc. carries a high price-to-earnings ratio of 40.56, which is significantly above the broader market average, suggesting that the stock is expensive relative to its current earnings and may be overvalued if growth slows or if the company fails to meet elevated expectations.
  • Short interest in the stock has increased slightly to 8,021,680 shares as of October 30, 2026, with a days-to-cover ratio of 3.67, indicating that a notable portion of the market is betting against the stock's price appreciation.
  • The company's beta of 1.46 indicates that Illumina, Inc. is more volatile than the overall market, meaning investors should expect larger price swings and higher risk compared to less volatile sectors or companies.

ILMN Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $244.24, with a high forecast of $310.00 and a low forecast of $137.00.

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 3 sell ratings, 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.

According to analysts, Illumina's stock has a predicted upside of 23.51% based on their 12-month stock forecasts.

Over the previous 90 days, Illumina's stock had 3 downgrades and 2 upgrades by analysts.

Analysts like Illumina more than other "healthcare" companies. The consensus rating score for Illumina is 2.37 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how ILMN compares to other companies.


MarketBeat monitors more than a dozen sources for Illumina analyst ratings, with the most recent rating issued on 11/2/2026.
From Our Partners